DANA 2018 starts with us - Drug and Alcohol Nurses Australasia
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
DANA 2018
DRUG AND ALCOHOL NURSES OF AUSTRALASIA
It
star ts
with us
AUSTRALASIAN
CONFERENCE
26th and 27th July 2018
Royal Melbourne Institute of Technology
N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
General information
COMPLIMENTARY WI-FI NETWORKING DRINKS
Login details are: You were encouraged to
Username: RMIT-Guest register for networking
Event Code: 300981 drinks on -line, prior to the
conference. Networking
CONFERENCE HASHTAG drinks are NOT included in the
#DANAconf2018 conference registrations.
INSTAGRAM: Those of you who registered for this event
www.instagram.com/dana.nurses/ will be provided with drink tickets and an
FACEBOOK: entry ticket. These are required to gain
www.facebook.com/DANA.nurses/ access to the venue.
DANA encourages delegates to tweet
and post to Instagram REGISTRATION DESK/SPECIAL
REQUIREMENTS
MOBILE PHONES The registration desk in Storey Hall will be
As a courtesy to others, please open at the following times:
ensure your mobile telephone is Thursday 26th July: 7:30am to 8:30am
switched off during sessions. Friday 27th July: 8:00am to 8:45am
To contact event staff please call
BE SURE TO SMILE! 0431 037 004
Delegates may be digitally recorded through
photographs and/or video recordings. TIMING
These images are likely to be used in DANA As a courtesy to others,
publications. If you do not wish your image please be seated at least five
to be published, please notify staff before minutes before the scheduled
the event. commencement time of each
session. Entry doors will be closed at the
NAME BADGES listed commencement time.
Be sure to wear your name badge always.
It is your official pass to sessions, refreshment TRADE EXHIBITION
breaks and networking drinks. The trade exhibition will be open for viewing
during morning tea, lunch and afternoon tea.
2 | DANA 2018 Australasian Conference ‘It Starts with Us’
N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
Welcome from the President of DANA
I
’d like to extend a personal welcome to
each of you and I hope that throughout
the course of the next two days there will
be an opportunity to say so in person.
Our Conference Committee has worked
hard to bring you an outstanding program
presented in a great and historic venue in the
heart of Melbourne.
Our profession is confronting a time of
change and a period of workforce transition.
The theme for this year’s event, It Starts with
Us, reminds us that we are each responsible
to shape its future. Consequently, we sure to visit them during the morning and
anticipate that this conference will open a afternoon tea and lunch breaks.
debate not only on critical issues associated
with problematic alcohol and other drug use, Again, I’d like to thank each of your for
but also with issues that will influence the attending DANA’s conference and bringing
delivery of services. your own expertise to our gathering.
This year we have delegates from all over My personal respect and thanks goes out to
Australia and New Zealand as well as our all of you.
keynote speakers from the USA and UK.
Please make the most of the opportunity to
network and discuss ideas with colleagues
Darren Smyth
from diverse backgrounds and with whom Darren Smyth
you would not normally meet. There will DANA President
also be time for networking so that you can
PO Box 8014
catch up with old friends and acquaintances, Woolloongabba Qld 4102
as well as make some new ones. ABN 84 944 72 4112
www.danaonline.org
This conference is only possible with the
support of our sponsors and exhibitors. Be
DANA 2018 Australasian Conference ‘It Starts with Us’ | 3
N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
Storey Hall, Royal Melbourne Institute of Technology Green Brain Room, Royal Melbourne Institute of Technology
DAY 1 Thursday 26th July 2018
STOREY HALL
0800 Registration at entrance
0900 Presidential welcome: Mr Darren Smyth
0910 Acknowledgement of country
0920 Who is that Addiction Nurse? International keynote: Professor Carmel Clancy
1015-1045 Sponsor Address Morning Tea Break
1100 The Adams. de Crespigny. Harvey Oration: Professor Margaret Hamilton
1130 The Melbourne injecting drug user cohort study (SuperMIX): Professor Paul Dietze
Transcending burnout: Strategies for AOD nurses to avoid severe role stress:
1200
Dr Alistair Ross
1230 – 1315 Lunch and Nurse Practitioner meeting
Winners and losers in American drug policy. International keynote:
1315
Professor Katherine Fornili
1400 Experiences of online counselling: Dr Michael Savic
1430 Lessons learned from sector reform: Mr Sam Biondo
1500 – 1530 Sponsor Address Afternoon Tea Break
1530 Gambling in an AOD context: Dr Jane Oakes
This is where our peeps are at: hospital drug and alcohol consultation liaison
1600
services: Dr Apo Demirkol
1630 Wrap up of day: Ms Jennifer Holmes
1700 Networking Drinks Storey Hall Foyer
Program may be subject to change
6 | DANA 2018 Australasian Conference ‘It Starts with Us’N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
Royal Melbourne Institute of Technology, Melbourne
DAY 2 Friday 27th July 2018
STOREY HALL
0700 – 0800 AGM
0800 Registration at entrance
Discovery and development of new therapeutics for addictions derived from
0900
cannabis and oxytocin: Professor Iain McGregor
0950 Buprenorphine Panel Supported by Indivior
1045 – 1115 Sponsor Address Morning Tea
1115 Failure to decline: older Australians and alcohol: Dr Sara Callinan
Integrating HCV treatment into a regional setting: Ms Morag Goodinson
1200
Supported by Gilead
The role of art therapy in a drug and alcohol treatment setting: Ms Ann Maree See
1230
(& activity into lunch break)
1300 – 1330 Lunch
1330 The Healing Ways Program: Mr Keith Randall
1400 AOD in mother and child health: Ms Sally Garson
The impact of performance and image enhancing drugs and the implications for
1430
alcohol and other drug nurses: Dr Scott Griffiths
1500-1530 Sponsor Address Afternoon Tea
1530 The US Opioid crisis. International keynote: Professor Dana Murphy-Parker
1615 Presidential close
Program may be subject to change
DANA 2018 Australasian Conference ‘It Starts with Us’ | 7CONSUMER HCP PORTAL
THE NEED TREATING DEPENDENCE SUBOXONE ® FILM THE LONG TERM ADDITIONAL RESOURCES
MANAGING
OPIOID DEPENDENCE
Opioid dependence is a chronic condition that has historically been linked to illicit heroin use, but over the last 15 years in
Australia there has been a considerable increase in the abuse of pharmaceutical opioids, usually prescribed or dispensed
for chronic pain.1 It has been estimated that up to 10% of Australian patients with chronic non-malignant pain treated with
opioids meet the criteria for dependence.2
Turn To Help is a site dedicated to the treatment of opioid dependence. In this website, you will find information that will
help you identify opioid-dependent patients in your practice, as well as guidance on how to manage their condition in the
long term.
How to treat codeine dependency with Suboxone
LEARN MORE
The need
Help determine whether your patients are at risk of opioid painkiller dependence.
LEARN MORE
Treating dependence
Find the right treatment option for your patients with opioid dependence.
LEARN MORE
Suboxone® Film*3 (buprenorphine hydrochloride/naloxone hydrochloride dihydrate)
Learn about treating patients with Suboxone® Sublingual Film, a treatmentN urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
Program: Green Brain Room
Friday 27th July 2018
1330-1530: Papers from selected abstract submissions
Steph Kershaw Stephen Ling Amy Faden Anne Carroll
Cracks in the ice: It’s not just about That’s not important The ‘Rainbow
disseminating mental health: right now’: can we Connection’:
evidence-based co-morbidities in a change the attitudes of meeting the needs
information cohort of patients clinicians in addressing of rainbow people
about crystal prescribed opioid and treating smoking and why it matters.
methamphetamine agonist treatment by behaviours? The
in Australia. a nurse practitioner. development of a
smoking cessation
network at The
Canberra Hospital.
David Dwyer Marguerite White Wendy Forder Ali Loom
You should write Medicinal Cannabis HCV treatment in Finding the diamond
that down! as harm reduction the NSP setting in the rough: nurse led
outreach at an NSP.
10 | DANA 2018 Australasian Conference ‘It Starts with Us’N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
Symposia: Green Brain Room
Friday 27th July 2018
0830- 1030: Cracking the Code Symposium
Supported by the Alcohol and Other Drug (AOD) Branch with
Population Health at NSW Health
A forum to explore why people, with AOD related
problems often fail to experience the person-
centred, safe, high quality interventions and care
that we all expect from our health systems.
Attend and be part of a truly interactive session
led by two of the most senior and distinguished
AOD nurses from NSW Health, each known for
their individual dynamism, unique style and depth Jennifer Holmes Tonina Harvey
of experience.
Workshop components
• Cracking the code of silence and stigma which surrounds people with AOD issues.
• Expectations of care in a generalist nursing or midwifery setting.
• Key principles when working with people who use AODs.
• Challenges and barriers.
• Facilitating sustainable change.
1115- 1245: North Richmond Medically Supervised Injecting Centre
What’s the backstory to the Medically Supervised
Injecting Centre opening in North Richmond this
year?
Attend the MSIC Symposium to find out from:
• Judy Ryan: The Residents of Victoria Street
• Representatives of the North Richmond
Community Health
• Julie Latimer: NUM at the Sydney MSIC
• Melanie Walker:CEO of the Australian Injecting
Julie Latimer Melanie Walker
and Illicit Drug Users League
DANA 2018 Australasian Conference ‘It Starts with Us’ | 11N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
Our keynote speakers supported by a
grant from the Ian Potter Foundation
Carmel Clancy Dana Murphy-Parker Katherine Fornili
(PhD, RGN, RMN, BSc (Hons), (MS, CRNP, PMHNP-BC, (DNP, MPH, RN, CARN, FIAAN)
PG Cert HE, FPH, ICAPIII) CARN-AP, FIAAN)
Katherine is a public health
Carmel has dedicated a great Dana has developed her nurse and a certified addiction
deal of her career to facilitating expertise as a Mental Health/ registered nurse. She has worked
a competent workforce that Addiction nurse over the last in city and state government as
supports those most impacted twenty years. Right now she a behavioural health program
by addiction and mental health is an Assistant Professor in the planner and program consultant
issues. Widener University School of before joining the faculty of the
She is currently a Professor of Nursing and the immediate Past University of Maryland School of
Addiction and Mental Health and President of the International Nursing in 2005.
Head of Department at Middlesex Nurses Society on Addictions
She is President-Elect of the
University, London. (IntNSA).
International Nurses Society on
Carmel established the first Addictions (IntNSA) for 2016-
masters’ programme in ‘dual 2018, and an Associate Editor
diagnosis’ in Europe. For her for the Journal of Addictions
doctorial work Carmel explored Nursing.
workforce development and
career stages of specialist
addiction nurses.
12 | DANA 2018 Australasian Conference ‘It Starts with Us’PROUDLY SUPPORTED BY
N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
Our sponsors
DANA would like to acknowledge the support of conference sponsors and exhibitors.
GOLD SPONSOR SILVER SPONSOR BRONZE SPONSOR
BRONZE SPONSOR VENUE SPONSOR KEYNOTE SPONSOR
TWEETING SPONSOR
Our exhibitors
DANA RMIT
Indivior Victorian Alcohol and Drug Association
Gilead Biomed
Abbvie Nursing and Midwifery Health Program
MSD
14 | DANA 2018 Australasian Conference ‘It Starts with Us’N urses
ol o
h f
o
A
c l
us
ug & A
t r a l asia
Dr
P E C I A
S NFERENCE L
https://www.danaonline.org/
CO
O F F E R
• Join DANA for $100
Join
DANA fo
only $10 r
SPECIAL
0!
OFFER
• Re-new or extend your DANA membership for $100
• Hurry! This offer ends at midnight on 27.7.2018
• Click here then scroll down to ‘Conference Special Offer $100’
www.danaonline.orgIT’S SIMPLICITY THAT SETS
EPCLUSA APART IN
CHRONIC HEPATITIS C*1
Sir Edmu
Edmund
nd Hilla
Hillary
ry - Fir
First
st perso
person
n to cl
climb
b Mount
unt Eve
verest
restt
*Versus other sofosbuvir-containing regimens.2,3 EPCLUSA is the only pangenotypic single-tablet regimen
with one recommended treatment duration for all indicated patients in chronic hepatitis C.1,4 Recommended
treatment regimen for patients with decompensated cirrhosis is EPCLUSA + RBV for 12 weeks.1
GT ALL HCV GENOTYPES1 ONE PILL, ONCE A DAY FOR 12 WEEKS†1
1-6
†Recommended treatment regimen for patients with decompensated cirrhosis is EPCLUSA + RBV for 12 weeks.1
EPCLUSA® PBS Information: EPCLUSA is PBS listed for the treatment of chronic
genotype 1–6 hepatitis C infection in adults. Dual General Schedule and S100 [HSD] listing.
Authority required. Refer to PBS Schedule for full authority information.
Please review the Approved Product Information before prescribing.
Full Product Information is available from Gilead Medical Information: 1800 806 112.
Minimum Product Information – EPCLUSA® (sofosbuvir/velpatasvir) 400/100 mg tablets. INDICATIONS: Chronic Hepatitis C
(CHC) infection in adults. DOSAGE AND ADMINISTRATION: One tablet daily, orally for 12 weeks. Coadministration with ribavirin
for patients with decompensated cirrhosis. CONTRAINDICATIONS: Hypersensitivity, concurrent use with other medicinal products
containing any of the same active components. PRECAUTIONS: Symptomatic Bradycardia when coadministered with amiodarone,
(coadministration is not recommended). Hepatitis B virus Reactivation. Use with Potent P-gp Inducers and/or Moderate to
Potent CYP inducers. Pregnancy (Category B1 – EPCLUSA, Category X – Use with Ribavirin). If ribavirin is coadministered
with EPCLUSA, the contraindications regarding use of ribavirin apply (refer to ribavirin PI). DRUG INTERACTIONS: Acid Reducing
Agents, antiarrhythmics (amiodarone), vitamin K antagonist anticoagulants, anticonvulsants, antimycobacterials, antiretrovirals, St
John’s wort, HMG-CoA reductase inhibitors. ADVERSE EFFECTS: Headache, fatigue, nausea, and nasopharyngitis. This is not
a full list – for more details/complete list of adverse events refer to full Product Information.Full Product Information is available
from Gilead Sciences Pty Ltd and should be reviewed before prescribing EPCLUSA. Date of preparation 16 February 2018.
ABBREVIATIONS: GT: genotype. HCV: hepatitis C virus. RBV: ribavirin. REFERENCES: 1. EPCLUSA Approved Product Information.
2. HARVONI Approved Product Information. 3. SOVALDI Approved Product Information. 4. MAVIRET Approved Product Information.
Gilead Medical Information: 1800 806 112. EPCLUSA® is a trademark of Gilead Sciences, Inc.
©2018 Gilead Sciences Pty Ltd. Level 6, 417 St Kilda Road, Melbourne, VIC 3004.
EPC/AU/18-03/MI/1106. Ward6. GIEP13300WE. Date of preparation: March 2018.
16 | DANA 2018 Australasian Conference ‘It Starts with Us’You can also read
